Answers are grounded in this paper and cite their sources.
Narrative review uncovers mechanisms of cancer stem cell drug resistance, highlighting emerging targeted therapeutic approaches to prevent relapse.
Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are suggested to be responsible for drug resistance and cancer relapse due in part to their ability to self-renew themselves and differentiate into heterogeneous lineages of cancer cells. Thus, it is important to understand the characteristics and mechanisms by which CSCs display resistance to therapeutic agents. In this review, we highlight the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs. This promises new insights of CSCs in drug resistance and provides better therapeutic rationales to accompany novel anticancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Phi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: